The ACCUSCULPT™ procedure is an exciting body contouring treatment developed to meet the needs of patients seeking significant results with minimal downtime. It is ideal for areas such as the hips, thighs, knees, bra line, arms, and chest. Your physician uses the AccuSculpt contouring system to remove excess fat deposits that have settled in the target regions, which also results in overall skin tightening of the treated areas. Patented technology makes the procedure safer, more effective and less invasive than competing technologies.
Fat-dissolving and skin-tightening procedures for body contouring that are less invasive can seem oh-so-appealing when weighed against other options, such as liposuction. Some of the latest innovations include mesotherapy (lipodissolve), which involves the injection of various cocktails into the skin to dissolve fat, Thermage (also known as Thermacool or Thermalift), which uses radiofrequency to tighten facial skin for a "nonsurgical" face-lift, and LipoSonix, which uses high-intensity ultrasound to target and destroy fat cells.
CoolSculpting works by taking advantage of the fact that fat cells are more sensitive to cold than the other cells around them. This basic scientific fact was first discovered in 1970 by doctors observing children who sucked on popsicles for hours, and ended up having first soreness, and later dimples, caused by loss of fat cells! Fast forward about 20 years, and Harvard scientists revisited this fact, and realized that they could turn this science into a system for aesthetic sculpting of fatty bulges. The key was to find the ‘sweet spot’ of time and temperature, which would kill some fat cells but not damage surrounding structures such as skin. They called the public company that makes the systems Zeltiq. The proof of the success of this concept and treatment: Zeltiq was bought out by Allergan in 2016 for whopping 2.5 billion! This was the largest sale of a single medical device company in history.
1 July 2015: The CMA is considering whether it is or may be the case that this transaction has resulted in the creation of a relevant merger situation under the merger provisions of the Enterprise Act 2002 and, if so, whether the creation of that situation has resulted, or may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.
×